May 31, 2024, Chicago, Illinois, 6:30 PM – 8:30 PM Central Time (7:30 PM – 9:30 PM Eastern Time)

Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation

A CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Jonathan W Goldman, MD
Associate Professor, UCLA Hematology
and Oncology
Director of Clinical Trials in Thoracic Oncology
UCLA Health
Santa Monica, California

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Joel W Neal, MD, PhD
Associate Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Medical Director, Cancer Clinical Trials Office
Stanford Cancer Institute
Medical Director, Informatics Technology
Stanford Medicine Cancer Center
Stanford, California


Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Joshua K Sabari, MD
Attending Physician
Thoracic Medical Oncology
Assistant Professor of Medicine
NYU Langone Health
Perlmutter Cancer Center
New York, New York

Moderator
Helena Yu, MD
Medical Oncologist
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Taiho Oncology Inc.
Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

Discussion Topics

  • Evolving First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation
  • Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation
  • Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation
  • Contemporary Care for Patients with Nonmetastatic NSCLC with EGFR Mutations
  • Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation
  • Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Acknowledge available and emerging clinical trial findings with EGFR tyrosine kinase inhibitors (TKIs) for localized non-small cell lung cancer (NSCLC) with an EGFR mutation, and identify patients for whom this novel therapeutic approach would be warranted.
  • Counsel patients with metastatic NSCLC with EGFR mutations regarding available treatment considerations, explaining the relevance of mutation type, symptomatology, sites and extent of metastases, prior therapeutic exposure and other factors.
  • Evaluate the documented efficacy of chemotherapy combined with EGFR TKI therapy, and consider the role of this strategy as first-line treatment for patients with NSCLC with EGFR mutations.
  • Appreciate the biological rationale for dual inhibition of MET and EGFR in metastatic NSCLC with an EGFR mutation, and understand recently presented data establishing the benefit of this novel strategy for patients with newly diagnosed and relapsed/refractory disease.
  • Consider the scientific justification for targeting HER3 in NSCLC with an EGFR mutation, and review the structural components, mechanism of action and available research information with novel HER3-directed antibody-drug conjugates.
  • Understand the biology of EGFR exon 20 insertion mutations, and develop a strategy to optimally employ available therapies for patients with these genetic abnormalities.
  • Recognize common side effects associated with available and emerging agents with established activity in NSCLC with EGFR mutations, and develop supportive management strategies to minimize or ameliorate these toxicities.
  • Recall the biological rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with NSCLC with EGFR mutations.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Goldman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Advaxis Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, Spectrum Pharmaceuticals Inc, Vaccinex Inc. Dr Langer — Consulting/Advisory: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Merck, Mirati Therapeutics Inc, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Navire Pharma, Takeda Pharmaceuticals USA Inc, Trizell; Data and Safety Monitoring Boards/Committees: Incyte Corporation, Mirati Therapeutics Inc, Oncocyte, Razor Genomics, Summit Therapeutics; Medical Writing Support: Novartis; Nonrelevant Financial Relationships: Medscape, OncLive, Projects in Knowledge, RTOG Foundation, VA (VALOR). Dr Neal — Consulting/Advisory: AbbVie Inc, Amgen Inc, AnHeart Therapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, D2G Oncology Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Sanofi, Summit Therapeutics, Surface Oncology, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Research Funding (to Institution): AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Merck, Nektar Therapeutics, Novartis, Novocure Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationships (Honoraria): BioMedical Learning Institute (BMLI), Clinical Care Options, CME Matters, HMP Education, Medical Learning Institute Inc, Medscape, MJH Life Sciences, PeerView, prIME Oncology, Projects in Knowledge, Rockpointe, The Medical Educator Consortium. Dr Piotrowska — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Phanes Therapeutics Inc, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Travel Support: Janssen Biotech Inc; Nonrelevant Financial Relationship (Spouse): Employed by Blue Cross Blue Shield of Massachusetts. Dr Sabari — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Yu — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.

CONSULTING CLINICAL INVESTIGATORS
Roy S Herbst, MD, PhD — Advisory Committees: AstraZeneca Pharmaceuticals LP, BioNTech SE, Bolt Biotherapeutics, Candel Therapeutics, Checkpoint Therapeutics Inc, Cybrexa Therapeutics, EMD Serono Inc, Halozyme Inc, I-Mab Biopharma, Immune-Onc Therapeutics Inc, Immunocore, Infinity Pharmaceuticals Inc, Novartis, Ocean Biomedical, Revelar Biotherapeutics, Ribon Therapeutics, STCube, Xencor; Board Member (Nonexecutive/Independent): Immunocore, Junshi Biosciences; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics Inc, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, HiberCell, I-Mab Biopharma, Immune-Onc Therapeutics Inc, Immunocore, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, NextCure, Novartis, Ocean Biomedical, Oncocyte, Oncternal Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revelar Biotherapeutics, Ribon Therapeutics, Roche Laboratories Inc, Sanofi, WindMIL Therapeutics, Xencor; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Merck; Data and Safety Monitoring Boards/Committees: EMD Serono Inc, Halozyme Inc, Novartis, Scorpius Holdings Inc. John V Heymach, MD, PhD — Advisory Committees: AstraZeneca Pharmaceuticals LP, BerGenBio ASA, BioAtla, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Curio Science, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Licensing/Royalties: Spectrum Pharmaceuticals Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Mirati Therapeutics Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Taiho Oncology Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ASCO Annual Meeting.

IN-PERSON Registration
Thank you for your interest in our CME program taking place in Chicago. At this time online registration to attend this event in person is closed. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME, FIRST SERVED BASIS. Our onsite registration desk will be open at 6:00 PM central time on Friday, May 31st. If you are interested in attending, please visit our registration desk outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on the shuttle service is available on the 2024 ASCO Annual Meeting website.

Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.